Friday, July 10, 2026

pharma · Colitis, Ulcerative · Multiple Myeloma

Janssen Cilag International

Janssen Cilag International clinical programs — 3 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

São Paulo, EU HQ
13 Employees
EMA registrant Type
Company details
Status
Public
HQ
São Paulo, EU
Employees
13
Programs
46
Drugs
37
Patents
0
Intelligence · Clinical Programs

Janssen Cilag International projects

3 ClinicalTrials.gov programs sponsored by Janssen Cilag International.

Janssen Cilag International has 3 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. Guselkumab

    Janssen Cilag International NV

    Arthritis, Psoriatic

    approved small molecule active

    3 trials
  2. OROS hydromorphone

    Janssen Cilag International NV

    Cancer Pain

    approved small molecule completed

    1 trial
  3. Topiramate

    Janssen Cilag International NV

    Epilepsy

    approved small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does Janssen Cilag International have?

3 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.